Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and externally...
All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China...
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics...
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated...
BRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated...
All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T program Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR ⍺ Antagonist, Phase 3-ready) and...
BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated...
Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China Granted orphan drug designation from the European Medicines Agency...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer is no longer just a disease of aging populations. Researchers are sounding the alarm over rising...